How to buy VistaGen Therapeutics stock | 22 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy VistaGen Therapeutics stock in Canada

Own VistaGen Therapeutics shares in just a few minutes.

VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 11 staff and has a trailing 12-month revenue of around $647,600.

How to buy shares in VistaGen Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: VTGN in this case.
  5. Research VistaGen Therapeutics shares. The platform should provide the latest information available.
  6. Buy your VistaGen Therapeutics shares. It's that simple.

VistaGen Therapeutics share price

Use our graph to track the performance of VTGN stocks over time.

VistaGen Therapeutics shares at a glance

Information last updated 2021-04-16.
Latest market close$N/A
52-week range$0.35 - $3.18
50-day moving average $2.212
200-day moving average $1.5481
Wall St. target price$5.67
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.829

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
$0 account fee and free ETF transactions.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Deposit and trade $100 and get a $25 bonus.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Qtrade Investor
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 ETFs free of charge.
Qtrade Investor offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
Scotia iTRADE
Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy VistaGen Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

VistaGen Therapeutics financials

Revenue TTM USD$647,600
Gross profit TTM USD$0
Return on assets TTM -16.34%
Return on equity TTM -30.49%
Profit margin 0%
Book value $0.676
Market capitalisation USD$293.2 million

TTM: trailing 12 months

How to short and sell VistaGen Therapeutics shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "VTGN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 6.2 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 32.5% down from 9.2 million last month.

There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.

VistaGen Therapeutics's "short interest ratio" (SIR)

VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 1.9 million). VistaGen Therapeutics's SIR currently stands at 3.21. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 3210 shares are currently held short.

However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0434% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.

Find out more about how you can short VistaGen Therapeutics stock.

VistaGen Therapeutics share dividends

We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have VistaGen Therapeutics's shares ever split?

VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.

VistaGen Therapeutics share price volatility

Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.35 up to $3.18. A popular way to gauge a stock's volatility is its "beta".

VTGN.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.8174. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).

VistaGen Therapeutics overview

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site